Alert detail
LCD L39042: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer — WPS
What changed
WPS final LCD covers molecular biomarkers for prostate cancer risk—eff. 7/3/25
Who’s affected: Oncology billing teams · Effective: July 3, 2025
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 10 billing codes.
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.